Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Catherine Mazzacco, a director of Sight Sciences, Inc. (SGHT), reported on Form 4 that on 09/11/2025 she transferred 37,492 shares of the company's common stock to the Catherine Mazzacco Irrevocable Trust DTD 10/23/2023 for no consideration. The filing shows the Reporting Person remains a beneficiary of that Trust. After the reported disposition, the Form 4 lists 41,015 shares as beneficially owned following the transaction. The Form 4 was signed by an attorney-in-fact on 09/15/2025.
Sight Sciences reported that Brenton Taylor, EVP of Operations & R&D and a company officer, received a grant of 25,840 restricted stock units (RSUs) on September 2, 2025 under the 2021 Incentive Award Plan. Each RSU represents a contingent right to one share of common stock and the grant is described as equal to approximately $100,000 of common stock based on the closing price on the grant date. The RSUs vest in 16 equal quarterly installments beginning September 30, 2025 and continuing through June 30, 2029, subject to continued service; the RSUs have no expiration date. After the grant, the reporting person beneficially owns 185,840 shares (direct).
Sight Sciences, Inc. (SGHT) reported that Matthew Link, its Chief Commercial Officer, resigned effective 08/31/2025. The filing states that because of the resignation the reporting person is no longer subject to Section 16 obligations and will not file further Forms 4 or 5 for transactions in the issuer's equity. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
Sight Sciences, Inc. filed an insider report indicating that EVP of Research & Development Manohar K. Raheja is no longer a Section 16 insider. Effective August 31, 2025, his employment with the company terminated.
Because of this change, he will no longer be required to report transactions in Sight Sciences equity securities on Form 4 or Form 5. The filing does not list any specific stock transactions in its tables, focusing instead on the change in his reporting status.
Sight Sciences is launching a restructuring plan to cut operating costs and support its path to breakeven without additional equity capital. The company will reduce headcount by 43 employees, about 20% of its global workforce, trim research and development spending, limit marketing, travel and administrative costs, and leave some open roles unfilled. It expects a cash restructuring charge of approximately $2.7 million to $3.0 million and a non-cash reduction in stock-based compensation of about $0.6 million to $1.0 million, primarily in the third quarter of 2025. The workforce plan alone is estimated to yield around $11.9 million in annualized savings. The company also announced that its Chief Commercial Officer, Matthew Link, will step down effective August 31, 2025, with his severance included in the restructuring costs. Sight Sciences reaffirmed its 2025 revenue guidance of $72.0 million to $76.0 million, reiterated that third quarter 2025 surgical glaucoma revenue is expected to be down by mid-single digits year over year, and lowered its 2025 adjusted operating expense guidance to $95 million to $99 million from $101 million to $105 million.
Sight Sciences, Inc. (SGHT) – Form 4 insider transaction
Chief Technology Officer & Director David Badawi disclosed the sale of 5,679 common shares on 03 July 2025 at an average price of $4.174 per share. The disposition was executed to satisfy statutory tax-withholding obligations generated by the vesting of restricted stock units, as noted in the filing’s footnote.
Following the sale, Badawi’s direct beneficial ownership stands at 1,831,025 shares. No derivative securities were reported, and there were no purchases.
The Form 4 indicates an automatic, non-discretionary sale (code “S”) under Rule 16a to cover taxes, which generally carries less negative signaling than voluntary open-market sales. The transaction represents approximately 0.3 % of Badawi’s post-transaction holdings and an immaterial percentage of SGHT’s total shares outstanding.